CHMP Adopts Negative Opinion on Arimoclomol for Niemann-Pick Disease Type C – Zevra Therapeutics
Zevra Therapeutics announced that the CHMP has adopted a negative opinion regarding the Marketing Authorization Application (MAA) for arimoclomol for the treatment of Niemann-Pick disease type C (NPC),… read more.
